Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Arcutis Biotherapeutics (Nasdaq: ARQT) granted an aggregate 61,000 restricted stock units (RSUs) to 9 newly hired employees under its 2022 Inducement Plan. The awards, approved by the Board’s Compensation Committee, were granted July 1, 2026 and will vest 25% annually over four years, following Nasdaq Listing Rule 5635(c)(4).
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – ARQT
On the day this news was published, ARQT gained 1.01%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 30 | Virtual care launch | Positive | -2.0% | Launch of virtual health platform for chronic inflammatory skin disease care. |
| Jun 29 | Pediatric FDA approval | Positive | -2.0% | FDA approval expanding ZORYVE cream to plaque psoriasis patients aged 2–5. |
| Jun 05 | Inducement grants | Neutral | +0.2% | Prior RSU inducement grants to new hires under 2022 Inducement Plan. |
| Jun 03 | Clinical guidance | Neutral | +2.7% | Publication of expert consensus on genital psoriasis care in dermatology journal. |
| May 26 | Conference presentation | Neutral | +0.2% | Announcement of management presentation at major healthcare investor conference. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent Arcutis news, including a pediatric FDA approval and platform launch, has sometimes seen negative next-day moves despite generally constructive fundamentals.
Regulatory & Risk Context
Short interest appears elevated, indicating positioning that could contribute to sharper moves in either direction as sentiment changes.
An effective S-3ASR shelf lets Arcutis register multiple security types for potential offerings, and also permits selling securityholders to resell shares, with the company not receiving proceeds from those resales.
Key Terms
restricted stock units financial
nasdaq listing rule 5635(c)(4) regulatory
inducement plan financial
grant date financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
WESTLAKE VILLAGE, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 61,000 restricted stock units (RSUs) of Arcutis common stock to 9 newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of July 1, 2026, as a material inducement to the new employees in connection with their commencement of employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest over four years, with 25 percent vesting on each annual anniversary of the vesting commencement date, subject to each employee’s continued employment with Arcutis through the applicable vesting date.
Arcutis is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company delivering meaningful innovation to address the needs of individuals living with chronic inflammatory skin diseases. Over the past decade, Arcutis has successfully developed a robust portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases, driven by a commitment to solving the most persistent patient challenges in dermatology. Arcutis’ unique dermatology development platform, built on established scientific pathways and coupled with deep clinical dermatology and commercial expertise, enables us to efficiently develop, scale, and deliver our differentiated therapies while advancing a growing pipeline across a range of inflammatory dermatological conditions. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations and are subject to substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2026, as well as any subsequent filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com
Investors
Brian Schoelkopf, Head of Investor Relations
ir@arcutis.com
